Introduction {#s0005}
============

Porcine epidemic diarrhea (PED) is a highly contagious acute enteric disease characterized by vomiting, watery diarrhea, and severe dehydration of up to 80--100% mortality in suckling piglets ([@bib82], [@bib88], [@bib14], [@bib39]). PED was first reported in England in feeder and fattening pigs during 1970s ([@bib97]), and reemerged in Asia since 2010 with greater virulence and economic losses ([@bib8], [@bib54], [@bib72], [@bib101]). In the US, PEDV appeared for the first time in 2013 and severely affected most pig-producing states ([@bib9], [@bib59], [@bib62], [@bib86]). The causative agent is porcine epidemic diarrhea virus (PEDV), which belongs to the *Alphacoronavirus* genus in the family *Coronaviridae* (<http://ictvonline.org/virustaxonomy.asp>). PEDV is an enveloped virus with a single-stranded positive-sense RNA genome of approximately 28 kb in length with the 5′-cap and the 3′-polyadenylated tail. The PEDV genome is arranged with ORF1a, ORF1b, S, ORF3, E, M, N, in order with both termini flanking with the 5′- and 3′-untranslated regions (UTRs) ([@bib20]). ORF1a codes for the large polyprotein PP1a, while ORF1b is always expressed as a fusion protein PP1a/b with PP1a through a ribosomal frameshifting. PP1a and PP1a/b are further processed to 16 nonstructural proteins, nsp1 through nsp16. ORF3 codes for an accessory protein which is likely an additional nonstructural protein, whereas S, E, M and N genes code for four structural proteins ([@bib82]).

During viral infection, the sensing of foreign nucleic acids in the cytosol leads to the activation of an innate immune response to produce type I interferons (IFN-α/β) and establishes an antiviral state. The type I IFNs and IFN-mediated response provide a first line of defense against viral infection. The host innate immune system deploys the pattern-recognition receptors (PRRs) to sense and respond to the pathogen-associated molecular patterns (PAMPs) of virus ([@bib41]). This recognition triggers the activation of retinoic acid-inducible gene I (RIG-I) or melanoma differentiation gene 5 (MDA5), which further binds to the mitochondrial adapter protein MAVS/IPS-1 and recruits TNF receptor-associated factor 3/6 (TRAF3 and TRAF6). TRAF3 activates IκB kinase (IKK)-related kinases such as TANK-binding kinase 1 (TBK1) and IKKε for phosphorylation of interferon regulatory factors 3 and 7 (IRF3/IRF7) and type I IFN production ([@bib24], [@bib77]). TRAF6 leads to TANK1 activation, followed by NF-kB activation and cytokine production ([@bib73]). Upon TBK1 activation, phosphorylated IRF3 undergoes homodimerization and unveils the nuclear localization signal leading to the nuclear translocation, where it forms a complex with the transcription co-activator CREB (cAMP responsive element binding)-binding protein (CBP)/p300 ([@bib19], [@bib55], [@bib67]). The IRF3-CBP/p300 complex further binds to the positive regulatory domain (PRD) I--IV regions of the IFN-β promoter to assemble the enhanceosome together with NF-κB and other factors to turn on the transcription of type I IFN genes ([@bib32]). The IRF3--CBP/p300 interaction is crucial for IFN transcription. Following production and secretion, IFN molecules bind to the cell surface receptors and trigger the activation of Janus kinase--signal transducers and activators of transcription (JAK--STAT) signaling cascade. Phosphorylated STAT1 and STAT2 associate to form a heterodimer, which in turn recruits the IFN-regulatory factor 9 (IRF9) to form the IFN-stimulated gene factor 3 (ISGF3). ISGF3 translocates to the nucleus and induces genes regulated by IFN-stimulated response elements (ISRE), resulting in expression of hundreds of antiviral genes and establishment of an antiviral state ([@bib85]).

In turn, many viruses have evolved to counteract the host innate immune defense and such viral functions are often redundant. For *nidoviruses*, eleven and six viral proteins have been described as IFN antagonists for severe acute respiratory syndrome coronavirus (SARS-CoV) and porcine reproductive and respiratory syndrome virus (PRRSV), respectively ([@bib35], [@bib44], [@bib78], [@bib89], [@bib92]). For *Betacoronaviruses,* nsp1 has been reported as a multifunctional viral antagonist for innate immune response ([@bib34], [@bib64], [@bib95]). For PEDV, the viral modulation of innate immune signaling is poorly understood. PEDV infects Vero cells, but these cells are type I IFN-deficient due to a chromosomal deletion ([@bib16]). In the present study, we identified MARC-145 cells as a suitable line of cells for PEDV infection and for study of innate immune modulation. We showed that PEDV suppressed the type I interferon production and ISGs expression in these cells, and identified nsp1, nsp3, nsp7, nsp14, nsp15, nsp16, E, M, N and ORF3 as the viral IFN antagonists. We showed that PEDV nsp1 caused the CBP degradation by the proteasome-dependent pathway. The CBP degradation is a novel mechanism of coronavirus nsp1 for IFN suppression and our study provides a new insight into the immune modulation and evasion strategy of PEDV.

Results {#s0010}
=======

Infection of PEDV in Vero and MARC-145 cells {#s0015}
--------------------------------------------

PEDV replicates in the cytoplasm of villous epithelial cells of the small and large intestines ([@bib14], [@bib87]). The viral antigen is also detectable in the macrophages that infiltrated the lamina propria ([@bib49]). Histological studies showed that PEDV replicates in the porcine respiratory tract *in vivo* and transformed alveolar macrophages (3D4) *in vitro* ([@bib69]). Vero cells are widely used for PEDV for diagnosis, virus isolation, and research, but these cells are type I IFN-deficient due to the chromosomal deletion ([@bib16]). To study a possible regulation of innate immune signaling by PEDV, various cell lines were examined for susceptibility. Cells were infected with PEDV at an MOI of 0.1 in various trypsin concentrations and CPE was examined daily for up to 5 days. In Vero and MARC-145 cells, apparent CPE of multinucleation was observed by 24 h post-infection ( [Fig. 1](#f0005){ref-type="fig"}A and B, left panel). Trypsin activates the cleavage of S protein and induces membrane fusion to trigger infection ([@bib68], [@bib96]). PEDV infection was characterized by syncytia formation ([@bib31]) and infection foci were visualized by anti-PEDV M and N antibodies, indicating the susceptibility of both cell types for PEDV infection ([Fig. 1](#f0005){ref-type="fig"}A and B, middle and right panel). The viral proteins were detected using specific antibodies by western blot and the specific bands were corresponding to the M and N proteins, further confirming the productive infection of these cells by PEDV ([Fig. 1](#f0005){ref-type="fig"}C). The optimal trypsin concentration for PEDV propagation was 5 μg/ml and 2 μg/ml for Vero and MARC-145 cells, respectively. MARC-145 cells have been used to study type I IFN signaling of porcine arterivirus ([@bib43], [@bib66], [@bib70]), and thus infection of these cells by PEDV allowed us to study IFN modulation and signaling cascade.Fig. 1*PEDV infection in Vero and MARC-145 cells*. (A and B) Immunofluorescence showing the expression of nucleocapsid (N, green) and membrane (M, red) proteins in PEDV-infected cells. Vero and MARC-145 cells were infected with PEDV at an MOI of 0.1. Cells were fixed with 4% paraformaldehyde in PBS and stained with mouse anti-N monoclonal antibody (mAb) or rabbit anti-M polyclonal antibody (pAb). Arrows show multi-nucleated cells by fusion. (C) Detection of the N and M proteins in PEDV-infected cells. Cell lysates were prepared at 24 h post-infection, and Western blots were conducted using antibodies against N and M proteins.Fig. 1.

Suppression of IFN-β production in PEDV-infected cells {#s0020}
------------------------------------------------------

To determine whether PEDV infection antagonized the type I IFN response, IFN-β mRNA was determined in virus-infected cells. MARC-145 cells were infected with PEDV and stimulated with poly(I:C) followed by qRT-PCR for IFN-β mRNA using total RNA. As shown in [Fig. 2](#f0010){ref-type="fig"}A, PEDV infection did not induce the level of IFN-β mRNA expression whereas poly(I:C) alone induced the IFN-β gene expression effectively, indicating the suppression of IFN-β response by PEDV. To further evaluate the IFN-β response in PEDV-infected cells, a dual luciferase assay was performed. The results showed the suppression of IFN-β promoter activity in PEDV-infected cells upon poly(I:C) stimulation ([Fig. 2](#f0010){ref-type="fig"}B), demonstrating the modulation of IFN production by PEDV infection. IRF3 was additionally examined for its role for PEDV-mediated IFN-β suppression. The IRF3 promoter activity was found to be inhibited ([Fig. 2](#f0010){ref-type="fig"}C). The suppression of IFN-β production was confirmed by bioassay using VSV--GFP. VSV is sensitive to type I IFN treatment and thus commonly used for IFN bioassays. Culture supernatants were collected from PEDV-infected cells and were UV-irradiated, followed by incubation with MARC-145 cells and infection with VSV--GFP. VSV grew normally ([Fig. 2](#f0010){ref-type="fig"}D), whereas it did not grow with supernatants collected from poly(I:C)-treated cells for up to 1:8 dilution. VSV--GFP also grew normally with supernatants from both PEDV-infected cells with or without poly(I:C) stimulation, confirming the suppression of type I IFN production by PEDV.Fig. 2*Suppression of IFN-β production by PEDV*. (A) Inhibition of IFN-β gene transcription in virus-infected cells. MARC-145 cells were infected with PEDV at an MOI of 1 for 12 h in 12-well plates. Cells were transfected with poly(I:C) (0.5 μg/well) for 12 h, and qRT-PCR was conducted for IFN-β mRNA. Relative quantitation values for IFN-β mRNA are presented. (B and C), Regulation of IFN-β and IRF3 activities by PEDV. MARC-145 cells were co-transfected with pIFN-β-Luc (B), or pIRF3-Luc (C) along with pRL-TK in 12-well plates for 6 h followed by PEDV infection at an MOI of 1 for 12 h. Cells were then stimulated with poly(I:C) for 12 h, and cell lysates were prepared for dual-luciferase reporter assay. Results from three independent experiments were expressed as mean relative luciferase with standard deviation. Each experiment was carried out in triplicate. Asterisks indicate statistical significance calculated by the Student׳s *t* test. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. (D) VSV--GFP bioassay for IFN production. MARC-145 cells were infected with PEDV in 6-well plates at an MOI of 1 for 12 h and stimulated with poly(I:C) for 12 h. Cell culture supernatants were collected and UV-irradiated for 30 min. Fresh MARC-145 cells were grown in 96-well plates and incubated with supernatants of 2-fold serial dilutions of up to 1:32. After 24 h of incubation, cells were infected with VSV--GFP at an MOI of 0.1 for 16 h. GFP expression was assessed by fluorescent microscopy. Each dilution was tested in triplicate.Fig. 2.

Identification of viral IFN antagonists {#s0025}
---------------------------------------

The viral IFN antagonism is often redundant, and at least 11 viral proteins have been identified as IFN antagonists for SARS-CoV ([@bib44], [@bib78], [@bib92]). To identify such proteins for PEDV, we cloned PEDV genes representing nsps 1 through 16, and structural genes for S, E, M, and N including the ORF3 accessory protein gene ( [Fig. 3](#f0015){ref-type="fig"}A). Among these, nsp11 is a small oligopeptide generated from PP1a when ribosomal frameshifting does not occur and so was not included in this study. Each gene was inserted into the pXJ41 expression vector with the FLAG tag at either N- or C-terminus, and examined for IFN suppression. The protein expression of cloned genes was examined by immunofluorescence ([Fig. 3](#f0015){ref-type="fig"}B) and western blot ([Fig. 3](#f0015){ref-type="fig"}C) using anti-FLAG antibody. All genes were expressed as anticipated. HeLa cells were then co-transfected with an individual gene along with pIFN-β-Luc and pRL-TK, and reporter assays were conducted. PRRSV nsp1α (P-nsp1α) is known as an IFN-β suppressor, and its cystine mutant P-nsp1α(m) (C28S) is an IFN suppression revertant ([@bib29], [@bib81]), and so they were included as positive and negative controls, respectively. Poly(I:C) upregulated the IFN-β transcription in cells expressing pXJ41, GST, and P-nsp1α(m), while P-nsp1α suppressed the IFN-β promoter activity as expected ([Fig. 3](#f0015){ref-type="fig"}D and E). Of the nsps, nsp1, nsp3, nsp7, nsp14, nsp15 and nsp16 were shown to down-regulate the IFN-β activity ([Fig. 3](#f0015){ref-type="fig"}D). For structural proteins, E, M, and N were found to suppress the IFN induction ([Fig. 3](#f0015){ref-type="fig"}E), and ORF3 was additionally identified as an IFN suppressive protein ([Fig. 3](#f0015){ref-type="fig"}E). The findings from the reporter assays were validated by VSV--GFP bioassays. The dilution corresponding to 50% of cells exhibiting GFP expression was determined as the end-point inhibition. For pXJ41, GST, and nsp9, GFP expression was evident and their end-point inhibitions were determined as 1:64 ([Fig. 3](#f0015){ref-type="fig"}F). In contrast, the viral proteins identified as the luciferase suppressors showed an apparent inhibition of VSV--GFP replication and their end-points were determined to be 1:4 to 1:16 ([Fig. 3](#f0015){ref-type="fig"}F). These titers represent 4- to 16-fold lower than those of controls. Taken together, these data demonstrate that PEDV has the ability for IFN suppression, and nsp1, nsp3, nsp7, nsp14, nsp15, nsp16, ORF3, E, M and N are the viral IFN antagonists.Fig. 3*Cloning of PEDV genes and identification of viral proteins antagonizing type I IFN cascade*. (A) Genome organization of PEDV. The PEDV genome is organized as 5′ UTR-ORF1a-ORF1b-S(S1+S2)-ORF3-E-M-N-3′UTR in order. Sixteen nonstructural proteins encoded in ORF1a and ORF1b are depicted. (B and C) Confirmation of cloned gene expression. One μg of each of the cloned genes was transfected to HeLa cells in 12-well plates, and protein expression was determined by immunofluorescence (B) and Western blot (C) for each gene using anti-FLAG antibody. (D and E) Regulation of poly(I:C)-induced IFN-β promoter activity by individual PEDV proteins. HeLa cells were seeded in 12-well plates and co-transfected with pIFN-β-Luc along with individual PEDV genes and pRL-TK at a ratio of 1:1:0.1. Since the expression levels of nsp3 and nsp16 were low, three-times more plasmids were transfected for these genes to ensure the comparable level of protein expression. PRRSV nsp1α (P-nsp1α) is a known type I IFN suppressor, and the IFN-suppression of its mutant P-nsp1α(m) was lost. Both constructs were included as controls. At 24 h post-transfection, cells were stimulated with poly(I:C) (0.5 μg/ml) for 12 h and the luciferase activities were measured. The reporter experiments were repeated three times, each time in triplicate. Asterisks indicate the statistical significance. Statistical analysis was performed by Student׳s *t* test using GST as a control. ^⁎^*P*\<0.05, ^⁎⁎^*P*\<0.01 and ^⁎⁎⁎^*P*\<0.001. (F) VSV--GFP bioassay. The cell culture supernatants for IFN-β promoter luciferase assays were collected and diluted serially by 2-folds up to 1:64. Fresh MARC-145 cells were grown in 96-well plates and incubated with each dilution of supernatants for 24 h, and then infected with VSV--GFP at an MOI of 0.1 for 16 h. VSV replication was measured by monitoring the fluorescence by GFP expression using fluorescent microscopy. Data were presented as log~2~ sample dilution folds. (G) Inhibition of IRF3 promoter activation by PEDV proteins. The IFN antagonists were further examined for IRF3 activities by luciferase reporter assays. Statistical analysis was performed by Student׳s *t* test using GST as a control. ^⁎^*P*\<0.05, ^⁎⁎^*P*\<0.01 and ^⁎⁎⁎^*P*\<0.001.Fig. 3.

To determine the target for IFN inhibition, the IRF3 pathway was examined for individual viral proteins using the IRF3 luciferase reporter constructs. Upon stimulation, the IRF3-dependent luciferase expression was reduced by nsp1, nsp3, nsp7, nsp14, nsp15, nsp16, ORF3, E, M, and N, comparing to those of pXJ41 and GST ([Fig. 3](#f0015){ref-type="fig"}G). This suggests that the IRF3 signaling pathway was interfered by these viral proteins for the suppression of the IFN-β production.

PEDV nsp1 antagonism is a nuclear event {#s0030}
---------------------------------------

SARS-CoV is a *betacoronavirus* and its nsp1 triggers inhibition of type I IFN induction and downstream signaling, host mRNA decay and cleavage, and inhibition of protein translation ([@bib34], [@bib57], [@bib64], [@bib91]). Transmissible gastroenteritis virus (TGEV) is an *alphacoronavirus* and its nsp1 inhibits host protein expression ([@bib33]). Nsp1 of *alphacoronavirus* and *betacoronavirus* lacks the overall sequence similarity ([@bib65]), and thus *alphacoronavirus* nsp1 may have a distinct basis for its biological function. Since nsp1 appeared the most potent suppressor in our study on PEDV, nsp1 was chosen to study the molecular basis for the IFN suppression. The subcellular localization was first examined by confocal microscopy in transiently expressing cells. The nsp1 distribution was evident in the both nucleus and cytoplasm ( [Fig. 4](#f0020){ref-type="fig"}A), which is consistent with TGEV nsp1 ([@bib65]). Co-expression of nsp1 with either the endoplasmic reticulum or mitochondrial marker showed the site for cytoplasmic nsp1 in the endoplasmic reticulum ([Fig. 4](#f0020){ref-type="fig"}B). Quantitative RT-PCR was conducted to evaluate IFN-β suppression in nsp1-gene transfected cells. The expression of nsp1 significantly suppressed the IFN-β mRNA transcription ( [Fig. 5](#f0025){ref-type="fig"}A), further validating the nsp1 antagonism against IFN-β production. Subsequently, the IFN-mediated antiviral gene expression was examined for ISG15 and ISG56 by qRT-PCR. PEDV nsp1 reduced the poly(I:C)-stimulated mRNA levels of both ISG15 ([Fig. 5](#f0025){ref-type="fig"}B) and ISG56 ([Fig. 5](#f0025){ref-type="fig"}C), indicating the suppression of IFN signaling by nsp1. The suppression of IFN-β, IRF3, and NF-κB activations raises a possibility that nsp1 may target a component of the RIG-I like receptor (RLR) signaling pathway. To examine this premise, nsp1 was co-expressed with one of the main components in the RLR signaling pathway, and IFN luciferase activities were determined at 24 h post-transfection. The over-expression of IPS-1, or IRF3 led to the robust activation of the IFN-β promoter as anticipated, whereas the activation was significantly inhibited by nsp1 ( [Fig. 6](#f0030){ref-type="fig"}A and B). Collectively, it suggests that nsp1 targets the RLR pathway downstream of the IRF3 activation.Fig. 4*Subcellular localization of PEDV nsp1*. HeLa cells were seeded on slides in 6-well plates and transfected with PEDV nsp1 gene (A), or co-transfected with nsp1 and pDsRed2-ER or pDsRed2-Mito (B). At 24 h post-transfection, cells were fixed and permeabilized with Triton X-100. Cells were then incubated with rat anti-FLAG mAb for 1 h, followed by Alexa Fluor 488-conjugated goat anti-mouse (green) secondary antibody to visualize nsp1. The ER and mitochondrial proteins were fused with the ER and mitochondria targeting sequence (Clontech) and so directly visualized (red). Nuclei (blue) were stained with DAPI. Images were collected using a Zeiss LSM-510 META confocal laser-scanning microscope and processed with the LSM image browser (Zeiss).Fig. 4.Fig. 5*Inhibition of IFN-β and ISG expression by nsp1*. HeLa cells were seeded in 12-well plates and transfected with the nsp1 gene for 24 h, and stimulated with poly(I:C) for 12 h. Total RNA was extracted and mRNA expression was evaluated by qRT-PCR for IFN-β (A), ISG15 (B), and ISG56 (C). Results were normalized using β-actin mRNA and expressed as relative changes in mRNA levels with respect to those in cells without stimulation. Data are presented from three independent experiments, each in triplicate. Statistical analysis was performed by Student׳s *t* test. ^⁎^*P*\<0.05, ^⁎⁎^*P*\<0.01, and ^⁎⁎⁎^*P*\<0.001.Fig. 5.Fig. 6*Disruption of IRF3-mediated IFN signaling by nsp1*. HeLa cells were seeded in 12-well plates and co-transfected with pMAVS/IPS-1 (A) or pIRF3 (B) along with the nsp1 gene, pRL-TK, and IFN-β-Luc reporter for 24 h. Cells were harvested to measure the firefly and renilla luciferase activities. Relative luciferase activity was defined as a ratio of the firefly luciferase to renilla luciferase activities. Data are presented as mean value±standard deviation from three independent experiments. Statistical analysis was performed by Student׳s *t* test. ^⁎^*P*\<0.05, ^⁎⁎^*P*\<0.01, and ^⁎⁎⁎^*P*\<0.001.Fig. 6.

IRF3 is a resident protein in the cytoplasm. When stimulated, it is phosphorylated and homodimerized, leading to the translocation to the nucleus ([@bib19]). To determine whether PEDV nsp1 targeted the IRF3-dependent pathway, the IRF3 phosphorylation was first examined. nsp1-gene transfected cells were stimulated with poly(I:C), and the IRF3 phosphorylation was examined by western blot. As anticipated, the poly(I:C) stimulation led to IRF3 phosphorylation in pXJ41-transfected cells, and similarly, in nsp1-expressing cells, the IRF3 phosphorylation was evident and comparable to that of control ( [Fig. 7](#f0035){ref-type="fig"}A, top panel, lane 4), suggesting that PEDV nsp1 exerts its suppression downstream of the IRF3 phosphorylation. Thus, the nuclear translocation of IRF3 was next examined. PRRSV nsp1α is known not to block the IRF3 nuclear localization, and so was used as a control in this study. Endogenous IRF3 was normally diffused and distributed in the cytoplasm, but translocated to the nucleus when stimulated by poly(I:C) ([Fig. 7](#f0035){ref-type="fig"}B, second panel). Similarly to PRRSV nsp1α-expressing cells ([Fig. 7](#f0035){ref-type="fig"}B, fourth panel), IRF3 also localized normally in the nucleus after stimulation in PEDV nsp1-expressing cells ([Fig. 7](#f0035){ref-type="fig"}B, bottom panel), suggesting that the IFN suppression by PEDV nsp1 may be a nuclear event. The IRF3 nuclear translocation in nsp1-expressing cells was further confirmed by cell fractionation and western blot analyses. While IRF3 was phosphorylated and localized in the nucleus after stimulation, PEDV nsp1 did not inhibit the IRF3 phosphorylation and nuclear translocation ([Fig. 7](#f0035){ref-type="fig"}C), further indicating that the nsp1-mediated IFN suppression was a nuclear event.Fig. 7*IRF3 phosphorylation and nuclear translocation by nsp1*. (A) HeLa cells were transfected with the nsp1-expressing plasmid for 24 h, followed by poly(I:C) stimulation for 8 h. Cells were lysed and subjected to Western blot to determine phosphorylated (p) IRF3. (B) Immunofluorescence staining for IRF3 nuclear translocation by nsp1. HeLa cells were transfected with the nsp1-expressing plasmid (2 μg/well) in 6-well plates for 24 h and stimulated by poly(I:C) for 8 h. Cells were fixed and incubated with rabbit anti-IRF3 pAb and rat anti-FLAG mAb for 1 h. PRRSV nsp1α does not inhibit the IRF3 nuclear localization and was used as a control. Alexa Fluor 594-conjugated goat anti-rabbit and 488-conjugated goat anti-mouse secondary antibodies were used to visualize IRF3 (red) and viral nsp1 (green), respectively. Nuclei (blue) were stained with DAPI. Yellow arrows indicate IRF3 localization in the nucleus in the absence of nsp1 expression. White arrows indicate IRF3 localization in the nucleus in nsp1-expressing cells. (C) Phosphorylation and nuclear localization of IRF3 by nsp1. HeLa cells were transfected with the PEDV nsp1 gene for 24 h, then stimulated with poly(I:C) for 8 h. Cells were lysed for nuclear--cytoplasmic fractionations and subcellular distribution of IRF3 and pIRF3. Hsp90 was used as a cytosolic protein marker and PARP was used as a nuclear protein marker.Fig. 7.

Interruption of IRF3 and CBP association by nsp1 {#s0035}
------------------------------------------------

After nuclear translocation, an IRF3 dimer associates with the CREB-binding protein (CBP). This complex then binds to the PRD I--III regions of the IFN-β promoter to assemble the basal transcription machinery complex together with NF-κB and other transcription factors to turn on the transcription of type I IFN genes ([@bib32]). Thus, the IRF3--CBP/p300 interaction for the assembly of enhanceosome is crucial for IFN expression. Since PEDV nsp1 did not block the IRF3 phosphorylation and nuclear translocation in our study, it was hypothesized that nsp1 might disrupt the formation of enhanceosome in the nucleus. To address this, the IRF3/CBP association was first examined in nsp1-expressing cells. Cells were transfected with the nsp1 gene and stimulated with poly(I:C) followed by co-immunoprecipitation using anti-IRF3 antibody and immunoblot with anti-CBP antibody. In unstimulated cells, CBP was undetectable due to the absence of IRF3/CBP association ( [Fig. 8](#f0040){ref-type="fig"}A, left lane), but IRF3/CBP association became evident upon stimulation ([Fig. 8](#f0040){ref-type="fig"}A, middle lane). In nsp1-expressing cells however, the association of IRF3 and CBP disappeared even upon stimulation ([Fig. 8](#f0040){ref-type="fig"}A, right lane) and the detectable level of IRF3 remained unchanged ([Fig. 8](#f0040){ref-type="fig"}A, second panel). Absence of the association of CBP/IRF3 may occur when nsp1 binds to either IRF3 or CBP, or when IRF3 is unstable in the presence of nsp1. Since PEDV nsp1 was found to be a nuclear protein ([Figs. 4](#f0020){ref-type="fig"}A, B and [7](#f0035){ref-type="fig"}B, C), nsp1 in the nucleus might interact with either IRF3 or CBP. However, neither the interaction between IRF3 and nsp1, nor between CBP and nsp1 was observed by co-immunoprecipitation in our study. IRF3 was also stable in the presence of nsp1 ([Fig. 7](#f0035){ref-type="fig"}A and C), indicating that the absence of IRF3/CBP association was not due to the instability of IRF3. Interestingly, the level of CBP was found to decrease in nsp1-expressing cells ([Fig. 8](#f0040){ref-type="fig"}A), leading us to investigate the degradation of CBP by nsp1.Fig. 8*Degradation of CBP in PEDV-infected cells*. (A) Interruption of the IRF3 and CBP association by nsp1. HeLa cells were transfected with 2 µg/well of pXJ41-FLAG-nsp1 for 24 h and stimulated with poly(I:C) for 6 h. Cells were lysed and co-IP was carried out using rabbit anti-IRF3 and protein G-Agarose fast-flow beads (Millipore), followed by Western blot analysis using CBP antibody (panel 1, numbered from top) and IRF3 antibody (panel 2). Total cell lysates were probed for expression of CBP (panel 3), IRF3 (panel 4), nsp1 (panel 5), and β-actin as a loading control (panel 6). (B) Degradation of CBP in PEDV-infected cells. MARC-145 and Vero cells were seeded on coverslips placed on 6-well plates and grew to 80% confluency. Cells were infected with PEDV at an MOI of 0.1 for 24 h. Cells were then fixed and co-stained with rabbit anti-M pAb and mouse anti-CBP mAb. Alexa Fluor 594-conjugated goat anti-rabbit (red) and 488-conjugated goat anti-mouse (green) secondary antibodies were used to visualize protein expression. Nuclei (blue) were stained with DAPI. Yellow arrows indicate CBP in PEDV-uninfected cells. White arrows indicate CBP in PEDV-infected cells.Fig. 8.

Degradation of CBP by nsp1 is proteasome-dependent {#s0040}
--------------------------------------------------

Some viruses including HTLV, adenovirus, and an orthormyxovirus Thogoto interact with CBP to modulate type I IFN induction, suppress protein expression, or promote virus infection ([@bib23], [@bib36], [@bib37], [@bib98], [@bib102]). Degradation of CBP has been described for the porcine arterivirus PRRSV as a strategy for IFN antagonism ([@bib30]). Since the level of CBP was found to decrease in PEDV nsp1-expressing cells ([Fig. 8](#f0040){ref-type="fig"}A), CBP expression was validated in PEDV-infected cells by co-staining using anti-CBP antibody and anti-PEDV M pAb. In uninfected cells, CBP was predominately localized in the nucleus in MARC-145 and Vero cells ([Fig. 8](#f0040){ref-type="fig"}B, yellow arrows). In contrast, CBP was depleted in virus-infected cells ([Fig. 8](#f0040){ref-type="fig"}B, white arrows), demonstrating that the CBP was degraded by PEDV. We further sought to study whether the CBP degradation by PEDV was mediated by nsp1 protein. CBP was exclusively nuclear in control cells, whereas it was depleted in nsp1-expressing cells ( [Fig. 9](#f0045){ref-type="fig"}A). PRRSV nsp1α is known to degrade CBP in the nucleus ([@bib30]), and in PRRSV nsp1α-expressing cells, CBP was significantly depleted ([Fig. 9](#f0045){ref-type="fig"}A). The CBP degradation was quantified by examining the ratio of nsp1-expressing cells showing CBP degradation out of the chosen number of nsp1-expressing cells ([Fig. 9](#f0045){ref-type="fig"}B). Approximately 92% of PRRSV nsp1α-expressing cells showed more than 80% reduction of CBP, which is in consistent with the previous report ([@bib29]). For PEDV nsp1-expressing cells, approximately 90% cells showed more than 80% reduction of CBP, while no CBP reduction was observed in control cells. This finding was confirmed by western blot. In PEDV nsp1-expressing cells, CBP degradation was evident compared to that of control cells ([Fig. 9](#f0045){ref-type="fig"}C, top panel, lane 3). To eliminate a possibility that the reduction of CBP might be due to the short half-life of CBP, cyclohexamide (CHX) treatment was conducted ([Fig. 9](#f0045){ref-type="fig"}D). At 24 h post-transfection, cells were treated with CHX to shut down the new protein synthesis for indicated times followed by western blot. In nsp1-expressing cells, CBP reduction was evident at the beginning of CHX treatment, and further decreased by 2 h post-treatment. The CBP degradation was complete by 4 h post-treatment, whereas nsp1 and β-actin remained stable ([Fig. 9](#f0045){ref-type="fig"}D). Together, our data show that PEDV nsp1 was the viral protein contributing to the CBP degradation. Unlike PRRSV nsp1α, PEDV nsp1 does not contain a proteinase activity, and no direct interaction between CBP and nsp1 was identified in our study. It is thus unlikely that CBP would be a direct substrate of PEDV nsp1. Therefore, it was of interest to examine whether the CBP degradation was a proteasome-dependent process. The treatment with MG132 blocked the CBP degradation by nsp1. As little as 5 μM of MG132 was sufficient to inhibit the CBP degradation, and 10 μM was able to restore the CBP level back to the control level ([Fig. 9](#f0045){ref-type="fig"}E). To eliminate the CBP degradation by nsp1 was cell-type specific, we further tested the CBP degradation by nsp1 in pig intestinal epithelial cell line (IPEC-J2 cells), which reported to be susceptible to PEDV ([@bib104]). CBP degradation in nsp1-expressing cells was evident comparing to control cells ([Fig. 9](#f0045){ref-type="fig"}F, top panel). Additionally, The CBP degradation by nsp1 was also blocked by MG132 treatment in IPEC-J2 cells ([Fig. 9](#f0045){ref-type="fig"}F, bottom panel). This study indicates that the CBP degradation by PEDV nsp1 was proteasome-dependent in the nucleus.Fig. 9*CBP degradation in the nucleus is mediated by nsp1*. (A) CBP degradation by nsp1 as determined by immunofluorescence assay. HeLa cells were transfected with PRRSV nsp1α which is known to degrade CBP in the nucleus, or PEDV nsp1. At 24 h post-transfection, cells were fixed and co-stained with rabbit anti-FLAG pAb and mouse anti-CBP mAb. Alexa Fluor 594-conjugated goat anti-rabbit and 488-conjugated goat anti-mouse (green) secondary antibodies were used to visualize nsp1 (red) and CBP (green). Nuclei (blue) were stained with DAPI. Yellow arrows indicate CBP in the absence of nsp1 expression, and white arrows indicates CBP in cells expressing viral nsp1. (B) Percent number of cells in which CBP was degraded by PEDV nsp1 and PRRSV nsp1α (P-nsp1α). Data are presented by % calculation of transfected cells showing more than 80% reduction of CBP fluorescent intensity compared to the control CBP staining out of 150 randomly chosen nsp1-expressing cells. (C) CBP degradation by nsp1 determined by Western blot. At 24 h transfection, cells lysates were prepared for Western blot using mouse anti-CBP mAb to examine the level of endogenous CBP. (D) PEDV nsp1-mediated degradation of CBP after cycloheximide (CHX) treatment. After 24 h transfection with the nsp1 gene, cells were treated with 100 μg/ml of CHX for indicated times, followed by Western blot using mouse anti-CBP mAb (top panel) and mouse anti-FLAG mAb for nsp1 detection (middle panel). (E) Inhibition of nsp1-mediated CBP degradation by MG132. After 24 h transfection with the nsp1 gene, HeLa cells were treated with MG132 at indicated concentrations for 16 h. Cells lysates were prepared and western blot was conducted using mouse anti-CBP mAb (top panel) or mouse anti-FLAG mAb (middle panel). (F) The CBP degradation by PEDV nsp1 in porcine intestinal epithelial cells IPEC-J2. IPEC-J2 cells were maintained as described in the Material and Methods, and transfected with the PEDV nsp1 gene. At 24 h post-transfection, cells were treated with or without 10 μM MG132 for 16 h, and then fixed for IFA. Yellow arrows indicate CBP in the absence of nsp1 expression, and white arrows indicates CBP in cells expressing viral nsp1.Fig. 9.

Discussion {#s0045}
==========

The innate immune system is the first line of host defense in response to viral infection. It initiates the production of type I IFNs and proinflammatory cytokines through the recognition of PAMPs by PRRs and establishes antiviral states which are highly effective on resisting and controlling infections. In turn, many viruses have developed strategies to counteract the host innate immune response to establish productive infection. Previous studies have shown that PEDV infection fail to induce the IFN-β promoter activation and that PLP2 (papain-like proteinase 2) of PEDV antagonizes the IFN response by deubiquitinating RIG-I and STING ([@bib100]). The PEDV N protein suppresses the IRF3 and NF-κB activities and antagonizes the IFN-β production by disrupting the interaction between IRF3 and TBK1 ([@bib17]). On the contrary, a recent study shows that PEDV infection induces NF-κB activation in intestinal epithelial cells with the N protein as the activator ([@bib6]). In the present study, we have identified MARC-145 as PEDV permissive cells, and used these cells as a model to study the innate immune modulation for PEDV. We have shown the suppression of type I IFN production by PEDV, which is consistent with the recent finding in IECs ([@bib5]). We also have identified multiple viral proteins responsible for this suppression. We have further determined PEDV nsp1 as the viral component promoting CBP degradation in the nucleus via the proteasome-dependent pathway.

Many viruses in the order *Nidovirales* are able to modulate the host innate response, which plays an important role for their pathogenesis. In the family *Arteriviridae*, equine arteritis virus suppresses type I IFN production in equine endothelial cells ([@bib26]), and PRRSV also suppresses IFN production ([@bib1]). PRRSV is susceptible to type I IFNs in cells and the suppression of type I IFN varies for different isolates ([@bib1], [@bib50], [@bib66]). Mouse hepatitis virus (MHV), which is a *betacoronavirus,* induces a high level of IFN-α secretion by plasmacytoid dendritic cells (pDCs) during infection ([@bib7]). However, other cell types infected by MHV such as macrophages, microglia, and oligodendrocytes produce extremely low-levels of type I IFNs ([@bib53], [@bib74]; [@bib1001]). The MHV ns2 protein is dispensable for virus replication in cells but is required for induction of hepatitis in mouse ([@bib76]). The 2′,5′-phosphodiesterase (PDE) activity of ns2 mediates the cleavage of 2′,5′-oligoadenylate and prevents the activation of RNase L, while enhancing viral growth and pathogenesis, thus ns2 is a viral IFN antagonist ([@bib103]). SARS-CoV, which is another member virus in the genus *betacoronavirus,* impairs the IFN response in virus-infected cells, and an IFN therapy has been suggested to be efficacious for SARS patients ([@bib10], [@bib83]). MERS-CoV is also a *betacoronavirus,* and both MERS-CoV and SARS-CoV do not induce a pronounced IFN-response in polarized airway epithelial cells (Calu-3), alveolar adenocarcinoma cells (A549) and human monocyte-derived macrophages ([@bib48], [@bib105], [@bib106]). Even though the acute infection of TGEV induces a high-level of IFN-α in newborn pigs ([@bib46]), protein 7 counteracts the host antiviral response and influences viral pathogenesis ([@bib13], [@bib12]). The 7a protein of an *alphacoronavirus* feline infectious peritonitis virus is a type I IFN antagonist ([@bib15]). Type I IFNs of chickens inhibits viral replication and respiratory illness of the *gammacoronavirus* infectious bronchitis coronavirus (IBV) ([@bib71]). IBV delays the IFN response and the 3a and 3b accessory proteins have been identified as the IFN antagonists ([@bib45]). Thus, modulation of type I IFN response seems to be a common evasion strategy of viruses in the order *Nidovirales*.

We have shown in the present study the direct evidence that PEDV indeed downregulates type I IFNs production during infection. PEDV suppresses the IFN-β and IRF3 activities. Since IRF3 is a key element in the production of type I IFNs, our finding leads to a hypothesis that PEDV modulation of type I IFNs production targets the IRF3 signaling pathway. Interestingly, PEDV normally activates the NF-κB activity in Vero E6 cells ([@bib100]). A recent study confirms that PEDV infection in intestinal epithelial cells induces NF-κB activation ([@bib6]). In that study, nuclear localization of p65 increases by PEDV after 12 h through 48 h. However, activation of NF-κB during viral infection is generally an early event. For PRRSV, NF-κB is activated 30 min after infection ([@bib25]). Thus, how PEDV modulates NF-κB activation during early time of infection needs to be further investigated. We have identified at least ten viral IFN antagonists and all ten proteins inhibit the IRF3 activity. Whether these IFN antagonists modulate the NF-κB activity needs to be further investigated. The PEDV N protein suppresses Sendai virus-induced NF-κB activity in a dose-dependent manner ([@bib17]). In other study, N protein activates NF-κB in intestinal epithelial cells ([@bib6]). A possible explanation is that the NF-κB activation may be time-dependent and cell type-dependent. Together, the IRF3 signaling is likely the target by PEDV for type I IFNs modulation.

At least eleven viral proteins have been identified as IFN antagonists for SARS-CoV ([@bib44], [@bib78], [@bib92]), whereas ten proteins have been identified for PEDV in our study. Thus, coronaviruses seem to arm with multiple antagonists. A possible explanation for such a functional redundancy is that coronavirus genomes are the largest RNA known to biology and undergo continuous genetic evolution. When a functional mutation occurs in a major antagonist, other antagonists may complement the function to ensure efficient replication and adaptation in hosts. For SARS-CoV, nsp1 is a multifunctional protein with the suppressive activity for IFN and blocks the phosphorylation of STAT1 and degrades host cell mRNA ([@bib92]). SARS-CoV nsp14 and nsp15 works as exoribonuclease and endoribonuclease, respectively, thus specific digestion of dsRNAs and the consequent removal of RNA--PAMPs may lead to an inadequate activation of IFN response ([@bib44]). SARS-CoV nsp16 contains 2′-O-methlytransferase activity and modifies the cap of viral RNAs in order to evade the detection by the host immune system ([@bib92]). The SARS-CoV M protein impedes the formation of TRAF3·TANK·TBK1/IKKϵ complex for suppression of type I IFN production ([@bib80], [@bib79]). The PLP2 domain of SARS-CoV nsp3 negatively modulates type I IFN pathway and functions as a viral deubiquitinase. In our study, the full length PEDV nsp3 indeed inhibit the IFN activity. All ten antagonists identified for PEDV correspond to the respected antagonists of SARS-CoV. The corresponding proteins of PEDV may share the similar motifs and functions with those of SARS-CoV. Additionally, SARS-CoV encodes several accessory proteins. They are nonessential for viral replication but function as innate immune antagonists. For PEDV, ORF3 is the sole accessory protein, and a previous report shows that ORF3 functions as an ion channel protein and is relevant to infectivity and pathogenicity ([@bib94]). ORF3 is nonessential for viral replication *in vitro* as shown by targeted RNA recombination ([@bib52]). In our study, ORF3 is a potent IFN antagonist. The viral antagonists may target different pathways of the host innate immune signaling and their synergistic effects may shut down the host innate immune response more efficiently during the course of infection.

CBP is a histone acetyltransferase and plays a key role in transcription regulation. The CBP/p300 coactivators interact with hundreds of transcription factors including STATs, c-Myc, PIAS1, p53, NF-κB, and IRF family ([@bib2], [@bib27], [@bib58]). For IFN expression, the assembly of an enhanceosome consisting of NF-κB, IRFs, ATF2/c-Jun, and the architectural protein HMG I(Y) is required in response to virus infection. The IFN enhanceosome recruits CBP/p300 for synergistic activation of transcription ([@bib61]). Some viruses modulate the CBP activity for viral evasion. Two distinct regions in the simian virus 40 T antigen can independently alter the levels and loading of CBP/p300 transcripts onto polysomes for cell immortalization and transformation ([@bib75]). African swine fever virus nuclear protein A238L inhibits the expression of TNF-α by displacing the CBP/p300 coactivators ([@bib28]), and herpes simplex virus 1 (HSV-1) ICP0 protein recruits activated IRF3 and CBP/p300 to the nuclear foci, which may result in reduced transcription of IFN-β and inhibition of the host response ([@bib60]). HSV-1 VP16 protein inhibits NF-κB activation and interferes the recruitment of IRF3 to CBP to block the IFN-β production ([@bib99]). The ML protein of Thogoto virus interferes with IRF3 function without blocking its nuclear translocation but interrupts the association of IRF3 with CBP ([@bib37]), which is similar to the function of PEDV nsp1. The ML protein was later found to interact with the RNA polymerase II transcription factor IIB (TFIIB), however, this interaction hardly interferes the host general gene expression but strongly suppresses both the IRF3- and NF-κB-regulated promoter activities ([@bib93]). Thus, it is hypothesized that the virus-mediated CBP degradation may play a specific and key role for IFN modulation with a little impact on general cellular gene transcriptions. The degradation of CBP is a novel strategy for IFN modulation and has been extensively studied in the family of *Arteriviridae*, especially for PRRSV ([@bib30]). For PRRSV nsp1α, CBP degradation is associated with the zinc-finger motif and is likely the key mechanism for IFN suppression ([@bib29]). For PEDV, nsp1 is the most potent IFN suppressor among all viral antagonists without affecting the IRF3 phosphorylation and nuclear localization. In line with this, PEDV infection depletes the endogenous CBP. Furthermore, PEDV nsp1 disrupts the association of CBP--IRF3 and degrades CBP in a proteasome-dependent manner. SARS-CoV nsp1 inhibits type I IFN production, induces host mRNA degradation, and suppresses host protein translation ([@bib64]). However, the domains of SARS-CoV nsp1 responsible for suppression of host gene expression and type I IFN production are absent in PEDV nsp1 ([@bib34], [@bib64]). Even though nsp1s of *alphacoronavirus* and *betacoronavirus* share similar functions, they lack an overall sequence similarity and neither conserved motifs nor domains exist in viruses of *alphacoronaviruses*. Thus, it is plausible that nsp1 of *alphacoronaviruses* may have a distinct function regulating host innate immune responses and gene expression. TGEV nsp1 suppresses protein translation in cells and cell-free extracts. However, the suppression of protein translation by PEDV nsp1 may not be a general event since the β-actin shows the similar level of expression after infection and transfection. The lack of association of CBP-nsp1 and IRF3-nsp1 suggests that the CBP degradation by nsp1 is an indirect event that needs to be further determined. Similar to TGEV nsp1, the subcellular localization of PEDV nsp1 is nuclear--cytoplasmic. The sequence of PEDV nsp1 does not harbor any known nuclear localization signal, and thus nsp1 may piggy-bag a nuclear protein to enter the nucleus. The proteasome-dependent CBP degradation seems a unique viral tactic utilized to inhibit IFN-β production. It is of interest to study whether this is a common evasion strategy for coronaviruses.

CBP localizes in the PML nuclear bodies, which are discrete nuclear foci that are disrupted in acute promyelocytic leukemia ([@bib4], [@bib18], [@bib47]). The PML nuclear bodies dynamically colocalize with numerous proteins including CBP, PML, p53, Rb, sp100, DAXX, eIF4E, and SUMO ([@bib38]). Upon inhibition of proteasome activity, PML, sp100, EBNA-5, SUMO-1, and the 20S proteasome subunit move to the nucleolus, suggesting that proteasomal degradation occurs at the nuclear loci ([@bib3]). HAUSP, the ubiquitin-specific hydrolase in the PML nuclear bodies, removes ubiquitin moieties from proteins prior to proteasomal degradation ([@bib22]). Thus, PML nuclear bodies may represent the sites where ubiquitinated proteins are processed by enzymes such as HAUSP prior to degradation in the nucleolus ([@bib84]). Valproic acid, a histone deacetylase inhibitor, could induce CBP degradation through the ubiquitin--proteasome pathway, while increasing the colocalization of CBP with ubiquitin nuclear speckles and with PML nuclear bodies ([@bib84]), suggesting that PML nuclear bodies may be the sites for the ubiquitin-dependent degradation of CBP. It is of interest to examine whether PEDV nsp1 promotes ubiquitination of CBP for degradation in the nucleus and whether this degradation associates with PML nuclear bodies.

PEDV infects Vero cells and MARC-145 cells. Porcine amino peptidase N (pAPN) has been identified as the major cell entry receptor for PEDV ([@bib51], [@bib63]). Transient expression of pAPN confers PEDV non-permissive canine kidney cells (MDCK) to be permissive for PEDV infection. pAPN also increases the PEDV infectivity in porcine small intestine epithelial cells (IECs) ([@bib11]). The respiratory tract may support PEDV infection in pigs and the virus infects and replicates in transformed alveolar macrophages (3D4) *in vitro* ([@bib69]). Primate APN or receptor-independent pathways in Vero and MARC-145 cells may complement the function of pAPN for PEDV infection ([@bib90]).

In summary, we have shown the suppression of type I IFN production by PEDV and have identified specific viral IFN antagonists. Among these antagonists, nsp1 is the most potent protein and functions to degrade CBP in the nucleus. Our data provides a novel insight into the understanding of the immune evasion strategy of PEDV.

Material and methods {#s0050}
====================

Cells, viruses, antibodies and chemicals {#s0055}
----------------------------------------

HeLa cells (NIH AIDS Research and Reference Reagent Program, Germantown, MD) and MARC-145 cells ([@bib42]) were maintained in minimum essential medium (MEM) and Dulbecco׳s modified Eagle׳s medium (DMEM) (Mediatech, Manassas, VA), respectively, supplemented with 10% heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT). Vero cells (ATCC® CCL-81^TM^) were grown in DMEM supplemented with 10% FBS. The IPEC-J2 cell line is a continuous line of epithelial cells derived from the jejunum of a 12 h old, unsuckled mixed breed piglet and was obtained from Dr. Anthony Blikslager (North Carolina State University). IPEC-J2 was maintained in DMEM/F12 with 5% FBS supplemented with 5 µg/ml of insulin/selenium/transferrin (Life Technologies), and 5 ng/ml of epidermal growth factor (Life Technologies). PEDV (USA/Colorado/2013; GenBank: KF272920) was obtained from Agricultural Research Service US Department of Agriculture (Ames, IA). PEDV was propagated in MARC-145 cells with DMEM or Vero cells with MEM supplemented with 0.3% tryptose phosphate broth (Sigma, St. Louis, MO), 0.02% yeast extract (Teknova, Hollister, CA), and trypsin 250 (Sigma-Aldrich, St. Louis, MO). The trypsin concentration was 2 μg/ml for MARC-145 cells and 5 μg/ml in Vero cells. The recombinant vesicular stomatitis virus expressing green fluorescent protein (VSV--GFP) was kindly provided by Dr. A. Garcia-Sastre (Mount Sinai Hospital, New York, NY).

Polyinosinic:polycytidylic acid \[poly(I:C)\], DAPI (4′, 6-diamidino-2-phenylindole), and cycloheximide (CHX), rat anti-FLAG mAb were purchased from Sigma (St. Louis, MO). Human recombinant IFN-β and MG132 were purchased from Calbiochem (San Diego, CA). Anti-β-actin mAb (sc-47778), anti-CBP mAb (sc-7300), anti-hsp90 mAb (sc-69703), anti-PARP pAb (sc-7150), and anti-IRF3 pAb (sc-9082) were purchased from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA). Anti-phospho-IRF3 PAb (Ser396) were purchased from Cell Signaling (Danvers, MA). Rabbit anti-PEDV M pAb was kindly provided by Dr. Y. Fang (Kansas State University, Manhattan, KS). Mouse anti-PEDV N mAb was purchased from Medgene (Brookings, SD). Lipofectamine 2000 Transfection Reagent was purchased from Invitrogen (Carlsbad, CA). QIAamp Viral RNA mini kit and RNeasy mini kit were purchased from QIAGEN (Venlo, Limburg). Power SYBR Green PCR master mix was purchased from Life Technologies (Carlsbad, CA). Alexa Fluor 594-conjugated (goat anti-rabbit, red) and 488-conjugated (goat anti-mouse, green) secondary antibodies and Pierce™ ECL Western blotting substrate were purchased from Thermo Scientific (Waltham, MA).

Plasmids and gene cloning {#s0060}
-------------------------

The firefly luciferase genes were used as reporters with its expression under the control of various promoters as indicated below. The plasmid pIFN-β-Luc contains the entire IFN-β enhancer-promoter. The plasmid p4×IRF3-Luc contains four copies of IRF3 binding region PRD I--III of the IFN-β promoter. pIFN-β-Luc and p4×IRF3-Luc were obtained from Dr. Stephan Ludwig at Heinrich-Heine-Universität, Düsseldorf, Germany ([@bib21]). The Renilla luciferase plasmid pRL-TK (Promega) contains the herpes simplex virus thymidine kinase (HSV-tk) promoter and was included in all experiments to serve as an internal control. Active stimulator pMAVS/IPS-1 was obtained from Dr. J. Shisler (University of Illinois, Urbana, IL). pIRF3 was kindly provided by Dr. B. Gotoh (University of Fukui, Fukui, Japan). pDsRed2-ER and pDsRed2-Mito were purchased from Clontech.

Plasmids with the FLAG tag for expression of nsp1 through nsp16, and the S, S1, S2, ORF3, E, M and N genes were cloned from the viral genomic RNA by standard reverse transcription and PCR techniques using indicated primers ( [Table 1](#t0005){ref-type="table"}). Twenty-three viral genes were amplified and cloned into the eukaryotic expression vector pXJ41 using indicated restriction enzymes. The nsp1 to nsp16, ORF3, and N genes were expressed as fusion proteins with the N-terminal FLAG tag, and the S, S1, S2, E, and M genes were expressed as fusion proteins with the C-terminal FLAG tag to avoid the functional disruption of the signal sequence. The constructs were confirmed by sequencing, immunofluorescence, and western blot. PRRSV nsp1α and its cystine mutant P-nsp1α(m) (C28S) are described elsewhere ([@bib29], [@bib81]).Table 1Primers used for the cloning of PEDV nonstructural and structural genes (PEDV strain USA/Colorado/2013).Table 1**PrimerSequence (5׳-3׳)**nsp1-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}ATGGCTAGCAACCATGnsp1-RGCC[CTCGAG]{.ul}CTAACCACCACGACGnsp2-FGCC[GGATCC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}AACATCGTGCCAGnsp2-RGCC[GGTACC]{.ul}CTAACCACCTTTCTTCnsp3-FAGT[CTCGAG]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GGTGATGTCAAATTCnsp3-RGCC[AGATCT]{.ul}CTATGCACCCTTCTTATTTGnsp4-FGCC[GGATCC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GGTCTTCCTAGTTTTTCnsp4-RGCC[CTCGAG]{.ul}CTACTGTAGAGTTGAATTGnsp5-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GCTGGCTTGCGTAAGnsp5-RGCC[CTCGAG]{.ul}CTACTGAAGATTAACGCCnsp6-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}AGTGGTTATGTTTCnsp6-RGCC[CTCGAG]{.ul}CTACTGAACGGAAGnsp7-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}TCTAAACTGACTGnsp7-RGCC[CTCGAG]{.ul}CTACTGCAACATACnsp8-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}AGTGTTGCATCTACnsp8-RGCC[CTCGAG]{.ul}CTACTGGAGCTTGACnsp9-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}AATAATGAAATTATTCCnsp9-RGCC[CTCGAG]{.ul}CTACTGCAAGCGTACnsp10-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GCTGGTAAACAAACAGnsp10-RGCC[CTCGAG]{.ul}CTATTGCATAATGGATCnsp12-FGCC[GGATCC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}AGCACTGATATGGCnsp12-RGCC[CTCGAG]{.ul}CTATTGTAAAACTGCAGnsp13-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}TCTGCAGGGCTTTGTGnsp13-RGCC[CTCGAG]{.ul}CTACTGCAAATCAGnsp14-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GCTAATGAGGGTTGTGnsp14-RGCC[CTCGAG]{.ul}CTATTGCAAATTGTTACnsp15FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GGTCTTGAGAACATTGCnsp15RGCC[CTCGAG]{.ul}CTACTGAAGTTGCGGATnsp16FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}GCCAGTGAATGGAAGnsp16RGCC[CTCGAG]{.ul}TCATTTGTTTACGTTGS-FGCC[GAATTC]{.ul}ACCATGAAGTCTTTAACCTACS-RGCC[CTCGAG]{.ul}TCA[*CTTATCGTCGTCATCCTTGTAATC*]{.ul}CTGCACGTGGACCTTTTCS1-FGCC[GAATTC]{.ul}ACCATGATGAAGTCTTTAACCTACS1-RGCC[CTCGAG]{.ul}TCA[*CTTATCGTCGTCATCCTTGTAATC*]{.ul}AATACTCATACTAAAGS2-FGCC[GAATTC]{.ul}ACCATGAGGACAGAATATTTACAGS2-RGCC[CTCGAG]{.ul}TCA[*CTTATCGTCGTCATCCTTGTAATC*]{.ul}CTGCACGTGGACCTTTTCORF3-FGCC[GAATTC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}ATGTTTCTTGGACORF3-RGCC[CTCGAG]{.ul}TCATTCACTAATTGTAGE-FGCC[GAATTC]{.ul}ACCATGCTACAATTAGTGE-RGCC[CTCGAG]{.ul}TCA[*CTTATCGTCGTCATCCTTGTAATC*]{.ul}TACGTCAATAACAGTACM-FGCC[GAATTC]{.ul}ACCATGTCTAACGGTTCTATTCM-RGCC[CTCGAG]{.ul}TCA[*CTTATCGTCGTCATCCTTGTAATC*]{.ul}GACTAAATGAAGCACN-FGCC[GGATCC]{.ul}ACCATG[*GATTACAAGGATGACGACGATAAG*]{.ul}ATGGCTTCTGTCAGN-RGCC[CTCGAG]{.ul}TCAATTTCCTGTGTCGAAG[^3]

DNA transfection and luciferase reporter assay {#s0065}
----------------------------------------------

HeLa cells were seeded in 12-well plates and grown to 80% confluency prior to transfection. Individual viral protein genes, luciferase reporters, and pRL-TK as an internal control were transfected at a ratio of 10:10:1 in a total of 1.05 μg/well using Lipofectamine 2000 according to the manufacturer׳s instruction (Invitrogen). At 24 h post-transfection, cells were stimulated by transfection with 0.5 μg/well of poly(I:C) for 12 h. Cells were then lysed and luciferase assays were performed using the Dual Luciferease assay system according to the manufacturer׳s instructions (Promega). Values were normalized using the Renilla luciferase activity as the internal control and presented in fold-changes. Three independent assays were performed with each assay in triplicate.

Relative quantitative real-time RT-PCR {#s0070}
--------------------------------------

Total RNA was extracted from HeLa or MARC-145 cells using RNeasy mini kit according to the manufacturer׳s instructions (QIAGEN). The RNA was treated with DNase I to remove contaminating genomic DNA. Reverse transcription (RT) reaction was performed with 1 µg of total RNA using random primers and M-MLV reverse transcriptase (Invitrogen). SYBR Green real-time PCR was conducted in the ABI 7500 real-time PCR system according to the manufacturer׳s instructions (Life Technologies). The real-time PCR primers for IFN-β, ISG15, ISG56 and β-actin were listed in [Table 2](#t0010){ref-type="table"}. For each sample, the β-actin gene was amplified and used as an internal control. Specific amplification was confirmed by sequencing PCR products. The threshold cycle for target genes and the difference between their *C* ~t~ values (Δ*C* ~t~) were determined. The relative transcript levels of target gene are equal to 2^−ΔΔCt^ threshold method ([@bib56]) and are shown as fold changes relative to the respective untreated control samples.Table 2Primers used for relative quantitative real-time RT-PCR.Table 2**PrimerSequence (5׳-3׳)**IFN-β-FGATTTATCTAGCACTGGCTGGIFN-β-RCTTCAGGTAATGCAGAATCCISG15-FCACCGTGTTCATGAATCTGCISG15-RCTTTATTTCCGGCCCTTGATISG56-FCCTCCTTGGGTTCGTCTACAISG56-RGGCTGATATCTGGGTGCCTAβ-actin-FATCGTGCGTGACATTAAGβ-actin-RATTGCCAATGGTGATGAC

VSV--GFP interferon bioassay {#s0075}
----------------------------

HeLa cells were seeded in 6-well plates and transfected with 2 μg of plasmid. At 24 h post-transfection, cells were stimulated by transfection with 1 μg of poly(I:C) for 12 h. Supernatants were harvested for bioassay. For PEDV, MARC-145 cells were infected with PEDV at an MOI of 1 for 12 h prior to poly(I:C) stimulation. Supernatants from virus-infected cells were UV-irradiated for 30 min to remove infectivity prior to bioassay. The supernatants were then serially diluted by 2-fold. MARC-145 cells were freshly grown in 96-well plates and incubated with 100 μl of each dilution for 24 h. Cells were then infected in 100 μl of VSV--GFP at 10^4^ PFU/ml for 16 h and GFP expression was examined by inverted fluorescence microscopy (Nikon Eclipse TS100, 10×10). Each dilution was examined twice in triplicate each.

Indirect immunofluorescence assay (IFA) and confocal microscopy {#s0080}
---------------------------------------------------------------

Cells were seeded on coverslips and transfected with plasmids or infected with PEDV. For transfection of HeLa cells, total 2 µg of individual plasmids were transfected for 24 h using Lipofectamine 2000 according to the manufacturer׳s instructions (Invitrogen). Cells were then either treated with poly(I:C) for 12 h or IFN-β for 40 min. Cells were fixed with 4% paraformaldehyde in PBS overnight at 4 °C and permeabilized using 0.1% Triton X-100 for 15 min at room temperature (RT). After blocking with 1% BSA in PBS at RT for 30 min, cells were incubated with a primary antibody in PBS for 1--3 h. Cells were then washed three times with PBS and incubated with Alexa Fluor 488-labeled anti-mouse secondary antibody, or Alexa Fluor 594-labeled anti-rabbit secondary antibody (Thermo Scientific) for 1 h at RT in the dark. Cells were incubated with DAPI for 5 min at RT for nuclear staining. After washing with PBS, cover slips were mounted on microscope slides using Fluoromount-G mounting medium (Southern Biotech, Birmingham, AL), and visualized by fluorescence microscopy (Nikon Eclipse TS100). Confocal microscopy was conducted as described elsewhere ([@bib40]).

Cell fractionation {#s0085}
------------------

HeLa cells were seeded in 6-well plates to 80% confluency and transfected with 2 μg/well of nsp1 plasmid for 24 h. Cells were stimulated with 1 μg of poly(I:C) for 12 h and fractionated using the Nuclear/Cytosol Fractionation kit (BioVision, Milpitas, CA) with minor modifications. Briefly, cells were washed with cold PBS and collected using cell scrapers in 1 ml of cold PBS. Cell pellets were resuspended in 200 μl CEB-A buffer and incubated on ice for 10 min. After addition of CEB-B, tubes were vortexed and incubated on ice for 1 min. The cell lysates were then centrifuged at 4 °C 5 min at 16,000*g* and supernatants were collected as the cytosolic fraction. The cell pellets were suspended in NEB buffer and vortexed for 30 s and repeated 5 times every 10 min. The nuclear pellets were finally centrifuged for 10 min at 4 °C 16,000*g* and kept the supernatants as the nuclear fraction.

Western blot {#s0090}
------------

Cells were harvested in RIPA buffer \[20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethanesulphonyl fluoride (PMSF), 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40\] containing the proteinase inhibitors cocktail (Promega). Cells were frozen--thawed, collected in the pre-cold tubes, and centrifuged to remove insoluble components. Total protein concentration was determined using Pierce BCA protein assay kit (Thermo Scientific). Equal amounts of proteins were resolved by SDS-PAGE and blotted to PVDF membranes (Millipore). After blocking with 5% nonfat dry milk in TBST (0.05% Tween-20) for 1 h, membranes were incubated with a primary antibody in TBST containing 5% nonfat dry milk overnight at 4 °C, followed by washing and incubation with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at RT. The membrane was visualized using Pierce ECL Western Blotting Substrate (Thermo Scientific) and images were taken by FluorChem™ R System according to the manufacturer׳s instructions (ProteinSimple).

Co-immunoprecipitation {#s0095}
----------------------

Co-immunoprecipitation (co-IP) was performed as described previously with modifications ([@bib43]). Gene-transfected cells were lysed in lysis buffer \[50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM Na~3~VO~4~, 1 mM PMSF, 100 mg/ml leupetin, 1% NP-40, 10% glycerol\] supplemented proteinase inhibitors cocktail (Promega). Cell lysates were clarified by centrifugation at 4 °C for 10 min at 16,000*g*. Supernatants were transferred to fresh tubes and incubated with either FLAG- or IRF3-antibody at 4 °C overnight, followed by incubation with protein G Agarose beads (Fast Flow, Millipore) at 4 °C for 4 h. Pellets were collected by centrifugation and washed for five times. The final pellets were eluted with Laemmli sample buffer (Bio-Rad) and were subjected to western blot.

Statistical analysis {#s0100}
--------------------

Student׳s *t*-test was used for all statistical analyses. Asterisks indicate the statistical significance. \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.001.
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